ZA201104701B - Method for treating parkinson's disease using filamentous bacteriophage - Google Patents

Method for treating parkinson's disease using filamentous bacteriophage

Info

Publication number
ZA201104701B
ZA201104701B ZA2011/04701A ZA201104701A ZA201104701B ZA 201104701 B ZA201104701 B ZA 201104701B ZA 2011/04701 A ZA2011/04701 A ZA 2011/04701A ZA 201104701 A ZA201104701 A ZA 201104701A ZA 201104701 B ZA201104701 B ZA 201104701B
Authority
ZA
South Africa
Prior art keywords
disease
treating parkinson
filamentous bacteriophage
filamentous
bacteriophage
Prior art date
Application number
ZA2011/04701A
Other languages
English (en)
Inventor
Beka Solomon
Haim M Dimant
Original Assignee
Ramot At Tel-Aviv Univ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv Univ Ltd filed Critical Ramot At Tel-Aviv Univ Ltd
Publication of ZA201104701B publication Critical patent/ZA201104701B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2011/04701A 2008-11-24 2011-06-24 Method for treating parkinson's disease using filamentous bacteriophage ZA201104701B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
ZA201104701B true ZA201104701B (en) 2012-09-26

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04701A ZA201104701B (en) 2008-11-24 2011-06-24 Method for treating parkinson's disease using filamentous bacteriophage

Country Status (16)

Country Link
US (1) US20110286970A1 (enExample)
EP (2) EP2478911A1 (enExample)
JP (1) JP2012509672A (enExample)
KR (1) KR20110091778A (enExample)
CN (1) CN102223887B (enExample)
AU (1) AU2009316326A1 (enExample)
BR (1) BRPI0921557A2 (enExample)
CA (1) CA2744339A1 (enExample)
CO (1) CO6390112A2 (enExample)
IL (1) IL213120A0 (enExample)
MX (1) MX2011005430A (enExample)
NZ (1) NZ592928A (enExample)
RU (1) RU2011125971A (enExample)
SG (1) SG171791A1 (enExample)
WO (1) WO2010060073A2 (enExample)
ZA (1) ZA201104701B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
WO2002042321A2 (en) * 2000-11-24 2002-05-30 Isis Innovation Limited Mixed fibrils
IL163812A0 (en) * 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
JP5096169B2 (ja) * 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
MX2008010612A (es) * 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090324554A1 (en) * 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
AU2009316326A1 (en) 2010-05-27
MX2011005430A (es) 2011-10-28
CO6390112A2 (es) 2012-02-29
HK1162964A1 (en) 2012-09-07
SG171791A1 (en) 2011-07-28
EP2478911A1 (en) 2012-07-25
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
NZ592928A (en) 2012-12-21
IL213120A0 (en) 2011-07-31
CN102223887A (zh) 2011-10-19
EP2358377A2 (en) 2011-08-24
KR20110091778A (ko) 2011-08-12
WO2010060073A2 (en) 2010-05-27
WO2010060073A3 (en) 2010-09-02
CA2744339A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
CN102223887B (zh) 2013-11-06
RU2011125971A (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
GB2465897B (en) Respiratory disease treatment
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
ZA201008484B (en) Rasagiline for parkinson's disease modification
ZA201002751B (en) Compositions for treating parkinson's disease
PT2324126E (pt) Método de identificação de factores de risco da doença de alzheimer
ZA201007216B (en) Agent for treating disease
IL207892A0 (en) Agent for treating disease
IL207891A0 (en) Agent for treating disease
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
EP2485733A4 (en) METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL2350279T3 (pl) Sposoby leczenia chorób oczu
ZA200702027B (en) Process for relaxing or straightening hair
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL213120A0 (en) Method for treating parkinson' s disease
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
PT2341937E (pt) Composição para tratamento de doença
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2517698A4 (en) ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
GB0701456D0 (en) Treatment for respiratory disease
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
HK1175364A (en) Methods for treating parkinson's disease
GB0823568D0 (en) Respiratory disease treatment
GB0814488D0 (en) Respiratory disease treatment